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Summary Prostate cancer is the second leading cause of male death from malignant disease in Europe and in the USA. Failure to prevent
or eliminate metastatic dissemination is a fundamental problem underlying the current inadequate treatment of prostate cancer, and novel
therapeutic strategies are required if this disease is to be successfully managed. No independent markers are yet available to predict the
behaviour of any individual prostate cancer, particularly its potential to metastasize, and there is now an urgent prerequisite to identify and
characterize genes specifically involved in determining the metastatic phenotype of prostate cancer cells before any biologically appropriate
treatment modality can be devised. To identify DNA sequences that trophically promote the metastatic phenotype, we have established a new
transfection assay with which to monitor activity of prostate cancer genomic DNA. Rat prostatic G and AT6.1 cell lines derived from the same
original Dunning R3327 rat prostatic carcinoma exhibit, respectively, low- and high-metastatic phenotypes when grown in syngeneic
Copenhagen rats. Rat mammary epithelial cell line 'Rama 37' derived originally from Wistar-Furth rats yields benign non-metastasizing
adenomas when inoculated subcutaneously into syngeneic animals. In this report, the Rama 37 cell line is successfully used as the recipient
cell-line for transfected DNA fragments extracted from rat prostatic carcinoma G and AT6.1 cells. New metastatic variants of Rama 37 cells
have been generated. Enzymatically fragmented genomic DNA from rat metastatic prostate carcinoma cell lines was co-transfected together
with plasmid pSV2neo into parental Rama 37 cells, followed by culture in the presence of Geneticin-G418 to select for the transfected cells.
To enable subsequent identification of metastasis-promoting DNA sequences, the fragmented genomic DNA sequences were covalently
attached to specifically engineered linker DNA molecules to flank the genomic DNA before transfection. Thereafter, the resulting transfectants
were pooled and inoculated into mammary fat pads of female Wistar-Furth rats. Metastases produced by the transfectant cells in vivo were
reestablished from secondary tumours and probed for the presence of the specific synthetic oligonucleotide sequences that flanked, and
hence identified, the presence of the transfected DNA. These new metastatic cells are shown to provide a sensitive assay system with which
to detect DNA sequences responsible for conveying the metastatic phenotype of prostate cancer when inoculated into syngeneic rats.
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Adenocarcinoma ofthe prostate is now the most common human
non-cutaneous malignant neoplasm to affect men. In the USA
and Europe, it is the second leading cause of male deaths from
malignant disease after lung cancer (Foster, 1990; Boring et al,
1994). Despite the increasing incidence of this disease, current
knowledge of molecular mechanisms underlying proliferation
and dissemination of prostatic cancer cells remains limited
(Foster and Abel, 1992). Metastatic disease, involving multiple
genetic events, is responsible for the majority ofdeaths from this
disease. Establishment of an appropriate assay to identify
genetic changes expressed during the metastatic process is an
essential prerequisite to understanding the particular molecular
mechanisms responsible for dissemination of prostatic cancer.
Therefore, in vivo evaluation of the behavioural phenotype in
syngeneic animals is the only reliable biological assay with
which to confirm the metastatic capability of a population of
tumour cells.
Received 15 February 1997
Revised22July 1997
Accepted23July 1997
Correspondence to: S Foster
Previous work on the metastatic process has indicated that failure
to identify metastasis-associated genes is a serious omission within
the general field ofcancerbiology. The reasons are understandable:
first, it has been technically easier to search for known oncogenes
orformutations in tumour-suppressor genes; second, no appropriate
or reliable in vivo models with which to identify 'metastasis-
promoting' gene sequences have been available, until recently.
Early studies oftumorigenesis used DNA transfection together with
drug selection to identify activated cellular oncogenes in chemically
transformed mouse cells and in avariety ofhuman tumourcell lines
(Shih et al, 1979; Cooper et al, 1980; Krontiris and Cooper, 1981;
Shih et al, 1981; Reitsma et al, 1983). Genes such as the ras onco-
genes were discovered by this technique after transformation of
mouse NIH 3T3 fibroblasts. Typically, when inoculated into nude
mice at low cellular densities such transformants produced local-
ized, non-metastasizing, fibrosarcomas, whereas the parental cell-
lines failed toestablish tumours (Land et al, 1983). Currentevidence
suggests thatproduction ofmetastases by such tumourcells requires
additional genetic changes. Transfection of fragmented DNA from
human malignant tumours increases the metastatic frequencies of
both non-metastatic and low-metastatic cells (Van Roy et al, 1986;
Vousden et al, 1986; Waghorne et al, 1987; Glenn et al, 1988;
Radler-Pohl et al, 1988; Wallace et al, 1988).
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Figure 1 Controlled digestion of genomic DNA by different concentrations
of Hindlll. Lane 1, 5 units igg1; lane 2, 0.6 unitsgg-1; lane 3, 0.4 units ,ug-1;
lane 4, 0.2 units jig-1; lane 5, DNA molecular weight markers
To validate DNA transfection as a reliable assay for DNA
sequences involved in metastasis, the carcinogen-induced rat
mammary epithelial cell line known as 'Rama 37' was developed
(Dunnington et al, 1983). When transplanted into syngeneic rats,
this model yields benign adenomatous tumours with no metastatic
potential. Transfection of Rama 37 cells with Hindlll-fragmented
DNA extracted from rat and human metastatic malignant
mammary cells has resulted in the generation oftransfectants able
to metastasize to lungs and lymph nodes when inoculated into
syngeneic rats (Jamieson et al, 1990a; Davies et al, 1994).
Conversely, transfection of similarly fragmented DNA from
benign, non-metastasizing mammary epithelial cells does not
produce new cell strains with metastatic ability (Davies et al,
1994). Thus, it is transfection of a particular DNA sequence, and
not the transfection process itself, that is responsible for the gener-
ation ofmetastatic variants in this model (Chen et al, 1997).
In the present study, we report transfection of Rama 37 cells
with enzymatically fragmented genomic DNA from the Dunning
R3327 prostatic carcinoma G cell line (low metastatic potential)
and AT6.1 cell line (high metastatic potential). The Dunning
R3327 rat prostate carcinoma cell model is ideal for examining
different aspects of prostate cancer and metastasis as cells
exhibiting distinct behavioural phenotypes have been derived from
a single common origin, and many characteristics of the system
are similar to those of the human disease (Isaacs et al, 1986).
Using molecular biological techniques to 'tag' the fragmented
donor DNA before transfection (Chen et al, 1997), together with
the use of a reliable in vivo assay to detect spontaneous metas-
tases, we have successfully identified fragments ofdonor prostatic
DNA that become integrated into the genome of the resultant
transformants. These transformants yield metastatic tumours at
frequencies of 8.7% (G cell donor DNA) and 25% (AT6.1 cell
donor DNA) respectively. New cell-lines containing fragments of
donor prostatic DNA have been developed from these metastases.
The metastatic nature of these new cell lines has been further
confirmed by in vivo assay. As the transfected prostatic genomic
DNA was marked by flanking sequences of synthetic oligo-
nucleotides (Chen et al, 1997), these metastatic variants of Rama
37 cells now provide a unique resource with which genomic DNA
1; *****PCR primersequence******[
5' -AAT CCA AGC TTG CGG CCG ATC AGG CCG AAT ATG CGG CCG CATTAT-3'
3- A GGTTCG AAC GCC GGC TAG TCC GGC TTATAG GCC GGC GTA ATATCG A-5
Hindlll (I) Sfil Notl Hindlll (Def)
Figure 2 PCR primer sequence as described in Chen et al (1997)
Figure 3 Schematic diagram to show the generation of different Rama 37 transfectant cell lines and their interrelationships
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Table 1 Incidence of tumours and metastases produced by primary transfectants
Primary tumours
Cell-lines Donor Number of Median latent Incidence of
established by DNA animals Meansizes Incidence period oftumour Metastases
transfection inoculated (cm) Incidence(days)
Metastasis Metastasis
+ve -ve n % n %
Rama37 - 25 - 1.93 ±0.37 18 72 15 (12-16) 0 0
RMP1 G-cell 23 2.15 ± 0.13 2.01 ±0.39 22 95.6 14 (10-19) 2 8.7
RMP2 AT6.1 cell 20 2.07 ± 0.34 2.21 ± 0.41 20 100 13 (9-19) 5 25
RMP3 Rama 37 cell 21 - 2.24± 0.49 19 90 14 (11-17) 0 0
fragments responsible for the metastatic behaviour of rat prostate
cancer cells may be identified. Furthermore, this tested assay
system is now available to be applied to identify metastasis-
promoting sequences contained within genomic DNA from any
human malignancy.
MATERIALS AND METHODS
Preparation of tagged donor genomic DNA
Parental Rama 37 mammary epithelial cells and donorDunning rat
prostatic carcinoma G and AT6.1 cells were each grown to conflu-
ence in 15-cm-diameter Petri dishes, washed with phosphate-
buffered saline (PBS) at room temperature and harvested by
scraping with a sterile, siliconized rubber policeman into 30-ml
sterile, siliconized 30-ml Corex tubes. High molecular weight
genomic DNA was isolated using a DNA isolation kit (Flowgen,
UK). Partial digestion of the high molecular DNA with HindlIl
was performed to avoid significant damage to genes of potential
interest (Sambrook et al, 1989a). Before large-scale digestions
were undertaken, a series of pilot reactions were performed to
digest 1 gg ofgenomic DNA using different amounts ofHindlIl to
determine the most suitable concentration of the enzyme to
achieve fragments in the size range 5-25 kb (Figure 1).
A short synthetic double-stranded DNA sequence tag was used
to flank HindlIl-digested fragments ofgenomic DNA (Chen et al,
1997). Two complementary oligonucleotides (upper and lower
strands; Figure 2) were chemically synthesized and annealed by
heating at 65°C for 2 min followed by slowly cooling to room
temperature. The unique 22-base sequence engineered within the
synthetic oligonucleotides acts as both primers for subsequent
PCR reactions. Its structure prevents both mispriming and
oligomerization when used as a PCR primer to amplify the tagged
fragments ofgenomic DNA.
The HindIH partially digested genomic DNA fragments from
the G cells, from the AT6.1 cells and from the Rama 37 cells were
ligated to the synthetic oligonucleotide tags at a molecular ratio of
1:20 using bacterial T4 ligase. The reactions were performed at
16°C overnight. Excess unlinked oligonucleotides, and the
'flanked' DNA fragments were separated by agarose gel elec-
trophoresis in low melting point agarose. Genomic DNA frag-
ments linked to their synthetic flanking sequence were recovered
with a GENECLEAN kit (Bio 101, USA) and stored in absolute
ethanol at - 20°C until required for transfection studies.
A
Figure 4 Phase-contrast morphology of cells in monolayer tissue culture.
(A) Parental Rama 37 cells showing a distinct epithelial morphology similar to
that identified in the primary inoculants. (B) RMP 1 cell-line derived from a
pulmonary metastasis. (C) Cell line established from a pulmonary metastasis
produced by RMP 2 cells. (D) Cell line established from a cardiac metastasis
produced by RMP 2 cells. In contrast to the appearance of the original cells,
those of all three metastatic lines are small, fusiform in appearance and are
poorly cohesive
Co-transfection of Rama 37 cells with pSV2neo and
tagged DNA fragments
Calcium phosphate precipitation was used to perform the trans-
fection experiments (Jamieson et al, 1990a; Davies et al, 1994).
Exponentially growing parental Rama 37 cells were harvested by
scraping and seeded at a density of0.5-0.75 x 106 cells per 10 ml
of Dulbecco's modified Eagle medium (DMEM) in each 10-cm-
diameter Petri dish. After incubation overnight at 37°C, spent
medium was replaced with fresh DMEM at4 hbefore transfection.
Donor DNA fragments (18 gg) from each of the cell-lines G,
AT6.1 or Rama 37 and pSV2neo plasmid DNA (2gg) were precip-
itated with calcium phosphate by bubbling air through an 0.025 M
solution of Hepes containing 0.14M sodium chloride, 0.75 mM
sodium hydrogen phosphate and 0.125 M calcium chloride
(pH 7.1). The precipitated DNA calcium phosphate complex was
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Figure 5 Development of systemic metastases in syngeneic rats after inoculation of Rama 37 cells transfected with Hindlll-digested genomic DNA into the
mammary fat pad. (A) Lung metastasis produced by RMP 1 cells. (B) Lung metastasis produced by RMP 2 cells. (C) Lung and cardiac metastases produced by
RMP 2 cells
recovered in 1 ml of the solution and added directly to 10 ml of
DMEM medium covering 1 x 106 cells in each Petri dish. After
incubation for 12 h at 37°C, the medium was replaced by fresh
DMEM containing 10% (v/v) DMSO (Spandidos and Wilkie,
1984) at room temperature for 1.5 min. The medium was removed,
the cells washed once with fresh medium, and then incubated at
37°C for 24 h. The cells were passaged at a 1:10 dilution in a
selective medium comprising DMEM containing Geneticin-G418
at the concentration of 1 mg ml-'. Thereafter, this medium was
replaced every 3 or 4 days. Cell culture was continued for 1 week
after colonies became visible. When the colonies had grown to
more than 1.5-3.5 mm in diameter, the cells were harvested,
pooled and cultured continuously in identical selection medium
until large numbers of cells were obtained. The three cell pools
obtained by co-transfection of parental Rama 37 cells with frag-
ments of genomic DNA from prostatic G cells, AT6.1 cells or
benign mammary Rama 37 cells were designated RMP1, RMP2
and RMP3 respectively (Figure 3).
Tumorigenicity and metastatic ability of transfected
cells
The control Rama 37 cells and the three transfectant cell lines
were harvested by treatment with EDTA/trypsin and washed once
with PBS. Four groups, each comprising 25 female Wistar-Furth
(OLA strain) rats, 4- to 6-week-old, were used to assay the control
parental Rama 37 cells and the three transfected cell lines for their
tumorigenicity and metastasizing ability (Table 1). Each animal
was inoculated subcutaneously into the right inguinal mammary
fat pad with a depot of0.2 x 106 cells in PBS. Animals dying soon
after the ulceration of their primary tumour, or after inadvertent
inoculation of tumour cells into sites extending beyond the
anatomical confines ofthe mammary fat pads, were excluded from
the study. All surviving animals retained within the study were
autopsied at 3 months after inoculation. The lungs, liver, spleen,
kidney, heart and axillary lymph nodes in each animal were exam-
ined for gross metastases. Small pieces of tissue were taken from
organs containing macroscopically visible metastases. If an organ
was suspected ofcontaining metastases, it was minced and used to
re-establish tumour cells in culture in the presence of G418 to
confirm that they were oftransfectant origin.
A
Figure 6 Histological appearance of primary tumours produced by
transfected Rama 37 cells and the metastases that developed in rats
inoculated with different transfectant cells. (A) Appearance of primary RMP 2
tumours produced by transfected Rama 37 cells containing rat prostatic
cancer genomic DNA. The tumour is composed of small, predominantly
spindle-like tumour cells, with no glandular pattern. (B) Low-power
appearance of 'cannonball' metastasis in the lung produced by RMP 1 cells.
(C) RMP 1 tumour cells entering the vascular compartment from within one
of the primary deposits. (D) Histological appearance of RMP 2 cells invading
cardiac muscle. The tumour is composed of highly undifferentiated epithelial
cells that show no organizational features
Histological examination
Samples ofprimary tumours, and all tissues taken at autopsy, were
fixed in Methacam (methanol-inhibisol-acetic acid; 6:3:1), or in
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Table 2 Incidence of metastases produced by metastasis-derived cell lines
Cell line Number of animals Latent period Number of animals with Animals with
metastases metastases (%)
RMP1a-Lu 9 14 1 11
RMP1b-Lu 7 13 1 14.3
RMP2c-Lu 8 10 2 25
RMP2c-H 8 10 3 37.5
RMP2d-Lu 4 10 1 25
RMP1a-Lu, lung metastasis produced in animal 'a' by RMP1 cells (derived from Dunning G Cells); RMP1b-Lu, lung metastasis produced
in animal 'b' by RMP1 cells (derived from Dunning G cells); RMP2c-Lu, lung metastasis produced in animal 'c' by RMP2 cells (derived
from Dunning AT6.1 cells); RMP2c-H, cardiac metastasis produced in animal 'c' by RMP2 cells (derived from Dunning AT6.1 cells);
RMP2d-Lu, lung metastasis produced in animal 'd' by RMP2 cells (derived from Dunning AT6.1 cells).
neutral buffered formol saline, processed conventionally,
embedded in paraffin wax, sectioned onto glass slides and stained
with haematoxylin and eosin (Dunnington et al, 1983). Sections of
each tissue were examined by two independent observers.
Tissue culture
Rat mammary epithelial cell line Rama 37, and all derived cell
lines (Figure 4), were routinely cultured in DMEM, containing 5%
(v/v) fetal calf serum, 50 ng ml-' hydrocortisone and 50 ng ml-'
insulin (Dunnington et al, 1984). The reversible toxic effects of
Geneticin-G418 (Gibco Bio-Cult, Paisley, UK) on Rama 37 cells
(Southern and Berg, 1982) was optimal at 0.8-1.0 mg ml-'. The
primary culture technique used to re-establish tumourcells in vitro
was similar to that described by Dunnington et al, 1984. A small
piece of non-necrotic tissue containing metastatic nodules or
micrometastases was minced using sterile scalpel blades. The
tissue was homogenized in 10 ml of DMEM with a Teflon pestle
and the suspension allowed to sediment by standing at room
temperature for 1 minute. The supernatant was removed and incu-
bated at 37°C. The sediment was incubated in a rotary mixer, for
1 h at 37°C, in 20 ml of DMEM containing 2 mg ml-' collagenase
(type I). The digest was allowed to sediment for 1 min before the
supernatant from this step was combined with that from the
homogenization step. Both were then centrifuged at 800 rpm for
5 min at room temperature in an MSE bench-top centrifuge. The
cell pellet was washed in 20 ml of DMEM, resuspended in 10 ml
of DMEM containing Geneticin-G418 at a concentration of
1 mg ml-', and plated in 5-cm-diameter Petri dishes.
Nucleic acid hybridization
Southern blothybridization was performed according to Sambrook
et al (1989b). Total genomic DNA extracted from cells was
partially digested with HindIll to generate a range offragments of
molecular weight from S kb to 25 kb. Aliquots of 10 ,ug from each
preparation were subjected to agarose gel electrophoresis to sepa-
rate the DNA fragments. Standard DNA fragments were used as
molecular weight markers. The fragments of DNA separated by
electrophoresis were excised from the gel anddepurinated in 0.2 M
hydrochloric acid for 10 min, denaturated in 0.4 M sodium
hydroxide and 1 M sodium chloride for 45 min and neutralized in
0.5 M Tris-HCl containing 1 M sodium chloride (pH 7.2) for 15
min. DNA fragments were transferred onto a nylon membrane
(Amersham International, Amersham, UK), according to the
manufacturer's protocol. Cross-linking of DNA to the membrane
was achieved by exposing the blot to a 302 nm UV transillumi-
nator for 3 min.
An 881-bp fragment ofneo DNA was obtained by digesting the
pSV2neo vector with HindlIl and BssHII. This cDNA probe was
labelled with [a32P]dCTP to a specific activity ofbetween 6 x 108
and 1 x 109 d.p.m. per ,ug DNA using random primed synthesis
(Feinberg and Vogelstein, 1983). The oligonucleotide probe (the
lower strand ofthe short DNA synthetic linker) was labelled at the
5' terminus with [a32P]ATP, to a specific activity of 2.4 x 107
d.p.m. per gg, using a polynucleotide kinase (Pharmacia, Milton
Keynes, UK). Fordetection ofthe neo gene and the presence ofthe
short DNA linker, theradioactively labelled probes were incubated
with the DNA blots in a hybridization oven (Techne HB-10, Philip
Harris, UK) for at least 16 h, at the predetermined optimum condi-
tions. The hybridized probes were detected by autoradiography at
- 70°C using Kodak X-AR5 or X-O-Mat S film.
RESULTS
Preparation of tagged donor genomic DNA
Approximately 500jg of high molecular weight genomic DNA
was extracted from each of the weakly and highly metastatic rat
prostate cell lines, the G cells and AT-6.1 cells, respectively, and
the benign Rama 37 cells. To prevent damage to gene sequences of
possible interest, a partial enzymatic digestion of DNA was
performed by HindIlI cleavage so that the size of the resulting
fragments ranged between 5 and 25 kb (Figure 1). DNA fragments
of an ideal size (5-25 kb) were obtained at a ratio of 0.2 unit
enzyme per 1 jig of DNA, and digested at 37°C for 1 h. After
recovery of the partially digested genomic DNA, these fragments
were covalently 'tagged' with short synthetic DNA sequences
(Figure 2) using bacterial T4 ligase. After the ligation reaction,
excess unlinked 'tags' were separated from the genomic DNA by
electrophoresis in low melting agarose gel. About half of the
'tagged' DNA fragments were recovered from the agarose gel.
Co-transfection of Rama 37 cells with pSV2neo and
tagged DNA fragments
When cultured in Geneticin-containing selection medium, all three
co-transfectants yielded small colonies thatbecame visible 10 days
after co-transfection of Rama 37 cells with pSV2neo plasmid
DNA together with, but unlinked, donor DNA fragments from
Dunning G cells, AT6.1 cells and a control ofDNA from Rama 37
cells (Figure 4). Transfection frequencies of DNA from the three
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Figure 8 Southern blot analysis to confirm the presence of the drug
resistance neogene in the transfectant cell pools and in the malignant cell
lines established from the metastases, using an 881 bp neo cDNA fragment
excised by Hind IlIl and BSSH II to hybridize the genomic DNA from different
cells. Lane 1, RMP 1a-Lu; lane 2, RMP 1b-Lu; lane 3, RMP 2a-Lu; lane 4,
RMP2b-Lu; lane 5, RMP 2-H; lane 6, RMP 1; lane 7, RMP 2; lane 8, RMP 3,
Lane 9, Rama 37 (control)
Figure 7 Southern blot detection of donor DNA fragments in the malignant
variants and in their parental transfectant cells, using the lower strand of the
synthetic oligonucleotide 'tag' as a probe. (A) Transfectant pooled cells:
(1) DNA from the control Rama 37 cells; (2) DNA from RMP3 cells; (3) DNA
from RMP 1 cells; (4) DNA from RMP 2 cells. (B) Metastatic variants:
(1) DNA from RMP 1a-Lu; (2) DNA from RMP 2a-Lu; (3) DNA from RMP
2b-Lu; (4) DNA from RMP 2c-Lu; (5) DNA from RMP 2-H; (6) DNA from the
control Rama 37 cells
donor cell lines were 1.44 x 10-5, 2.16 x 10- and 1.98 x 10-
respectively. There were no significant differences between the
growth rates of the transfected cells and parental Rama 37 cells
(data not shown).
Tumorigenicity and metastatic ability of transfected
cells
A schematic diagram is provided (Figure 3) to illustrate the rela-
tionship of the parental Rama 37 cells with the transfectant cell
lines, and their resultant metastases. The mean latent period for in
vivo growth ofprimary tumours by non-transfected parental Rama
37 cells and three groups of transfectants was not significantly
different from one another (P < 0.5), ranging in their means from
13 to 15 days (Table 1). At autopsy, the primary tumours in each
group varied from 1.5 cm to 3.5 cm in diameter. Of the animals
inoculated with non-transfected parental Rama 37 cells, 72%
developed palpable primary tumours by 3 months after inocula-
tion. In the three transfectant groups, the numbers oftumours were
significantly greater than in those not transfected with Rama 37
cells, ranging from 90% to 100% (Fisher's exact test, P < 0.05).
No metastases were identified either macroscopically or histo-
logically in the two control groups of animals inoculated with
parental (non-transfected) Rama 37 cells or with Rama 37 cells
autotransfected with Rama 37 genomic DNA (RMP3). In contrast,
metastases occurred in both transfectant cell lines containing
genomic DNA from either low- or high-metastatic prostatic carci-
nomas. Pulmonary mestastases developed in 2 out of 22 tumour-
bearing animals in group RMP1 (G-cell donor DNA transfectants).
Of these, one metastatic deposit was identified macroscopically at
autopsy (Figure SA). The second deposit was discovered on histo-
logical examination. In group RMP2 (AT6. 1-cell donor DNA trans-
fectants) 5 out of20 tumour-bearing animals developed pulmonary
metastases (Figure SB). Strikingly, a cardiac metastasis localized in
the apex ofthe heart (Figure SC) occurred in one ofthe five animals
in which lung metastases also developed.
The average sizes ofprimary tumours among all four groups of
animals at the end of the experiments were not significantly
different from one another (P < 0.03). The average size of the
primary tumours in animals inoculated with Rama 37 cells was
1.93 0.37 cm diameter, compared with 2.01 ± 0.39 cm,
2.21 + 0.41 cm and 2.24 ± 0.49 cm for those developed in rats
inoculated with RMP1 (G-cell DNA transfectants), RMP2 (AT6.1
cell DNA transfectants) and RMP3 (benign cell DNA transfec-
tants) respectively. The average sizes of the primary tumours that
produced metastases were 2.15 ± 0.13 cm and 2.07 ± 0.34 cm in
rats inoculated with RMP1 and RMP2 cells, respectively, and
compared with the average sizes of2.01 ± 0.39 cm and 2.21 ± 0.41
cm for primary tumours which did not produce metastases, but
which were developed from the identical transfectant cell stock
(RMP1 and RMP2) respectively. The sizes of the secondary
tumours varied greatly. The cardiac metastasis produced by RMP2
cells (AT6.1-cell DNA transfectants) was 6 mm in diameter. The
sizes of numerous lung metastases developed in the four animals
inoculated with RMP2 cells varied from 1 mm to 3 mm in diam-
eter. Both lung metastases produced by RMP1 cells (G-cell DNA
transfectants) in the two affected rats were not visible and were
much smaller than those produced by RMP2 cells. One of the
RMP1 metastases was found by microscopic examination ofhisto-
logical sections, the other was identified by primary tissue culture.
Apart from a few animals which developed ulcerated tumours,
and hence were excluded from further experiments, the rats
bearing only primary tumours (no metastases) did not exhibit
visible symptoms of illness during the period of the experiments.
For the four animals bearing metastases after inoculation ofRMP2
cells (AT6.1-cell DNA transfectants), symptoms of illness
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appeared gradually and increased in severity during the late stage
of the experiments. This was particularly apparent in the rat
bearing the cardiac metastasis. Before the end of the experiment,
this animal exhibited slow movements, increased cardiac rate,
dyspnoea, and failed to react to external stimulation. For the two
animals bearing lung metastases developing from the RMP1 cells
(G-cell DNA transfectants), no systemic symptoms were observed.
Histological examination
The primary tumours that developed in the two control groups
(parental Rama 37 and RMP3) appeared morphologically indistin-
guishable from one another. Both groups of tumours were encap-
sulated and comprised medium-sized and cytologically benign
epithelial cells arranged into partially solid and partially gland-like
patterns. In contrast, theprimary tumours thatdeveloped in the two
groups of animals transfected with prostatic carcinoma DNA
(RMP1 and RMP2) were composed ofsmall and highly malignant
looking spindle-shaped tumour cells (Figure 6A) that extensively
invaded into adjacent stroma and muscle.
The metastatic pulmonary lesions from the prostatic carcinoma
DNA transfectants ranged in size from 0.5 mm to 3 mm. The
pulmonary metastases produced by RMP1 (G-cell donor DNA
transfectants) consisted of nodules scattered throughout the lung
parenchyma (Figure 6B). Their likely origin from the primary
deposits was visible in several of the animals (Figure 6C). In
contrast, most of the nodules produced by RMP2 (AT6.1-cell
donor DNA transfectants) were either localized on the subpleural
surfaces of the lungs or located within the lung parenchyma adja-
cent to pulmonary vessels. Additional metastases from these
tumours were present within mesenteric lymph nodes. These
deposits were less numerous but larger (3-5 mm diameter) than
those produced by RMP1 (1.5-3 mm diameter).
The metastatic nodules produced by both RMP1 and RMP2
occurred as non-encapsulated tumours composed of small
fusiform malignant cells together with an infiltration of large
mononuclear and giant multinucleate cells of malignant cytology.
The cardiac metastasis produced by RMP2c-H comprised a non-
encapsulated mass of fusiform tumour cells together with some
tumour giant cells that infiltrated between cardiac myocytes and
effaced all normal tissues (Figure 6D).
Development of cell lines from metastases and their
metastatic potential
One pulmonary metastasis produced by RMP1, three pulmonary
metastases produced by RMP2 and the cardiac metastasis
produced by RMP2, were recovered at autopsy and successfully
re-established in primary tissue culture. Three additional metas-
tases discovered on histological examination initially grew in
tissue culture, but were too small to be rescued. The five success-
fully established metastatic variants were designated as RMPla-
Lu (lung metastasis 'a' produced by RMP1), RMP2a-Lu,
RMP2b-Lu, RMP2c-Lu (lung metastases 'a', 'b' and 'c' produced
by RMP2) and RMP2c-H (heart metastasis 'c' produced by
RMP2) (Figure 4).
In tissue culture, the cellular morphology of all the metastatic
variants appeared similar to one another, although very different
from that of the parental Rama 37 cells. Whereas the original
Rama 37 epithelial cells were large and predominantly cuboidal,
with only a very few elongated cells arising at the peripheries of
the colonies, the transfectant tumour cells from the metastases
typically appeared as small and loosely adherent spindle cells.
When these five new cell-lines were reinoculated individually into
five groups of syngeneic rats (second round transformants), 100%
tumorigenicity was observed (Table 2). All five groups ofanimals
developed metastases; further confirming the metastatic nature of
these Rama 37 variants.
Detection of the donor DNA fragments and drug
resistance gene
Genomic DNA extracted from RMP1, RMP2 and RMP3 cells,
digested completely with HindIlI and subjected to Southern blot
hybridization using the lower strand ofthe short DNA 'tag' as the
probe to detect donor DNA fragments, confirmed the presence ofa
few bands in all three cell pools (Figure 7A). In all five metastatic
cell lines, the presence of the short synthetic DNA linker was
confirmed. No band was detected in the genomic DNA from
control (untransfected) Rama 37 cells. The patterns of additional
bands in the three transfectant cell pools (RMP1-RMP3) were not
identical, the intensities of different bands varying between the
three cell lines. Within the RMP1 cell lines, only two bands with
sizes ofapproximately 10 kb and 3 kb were identified. RMP2 cell
lines revealed three bands with sizes ofapproximately 4.5 kb, 3 kb
and 1.3 kb. The RMP3 cell line contained a smear of bands in the
range from 5 kb to 2.5 kb with adistinctband at 1.3 kb. One ofthe
bands detected in all five cell lines established from metastases
(Figure 7B) was constant at about 1.3 kb. When an 811-bp-long
neo gene fragment excised from pSV2neo plasmid by HindIII and
BamHII was used as a probe to hybridize similar blots, a series of
bands was detected in the genomic DNA from all three pooled cell
transfectants and from all five new metastatic cell lines (Figure 8).
No band was detected in the negative control DNA from untreated
Rama 37 cells.
Because both ends of the transfected DNA fragment are
'tagged' by the same short DNA molecule, only one primer is
needed for performing PCR to amplify the 'tagged' DNA frag-
ments (see Figure 2). Using either the up or the low strand of the
short DNA 'tag' as a primer to carry out the PCR experiment on
the total genomic DNA extracted from the cell lines established
from the metastases, we have amplified and isolated 13 DNA frag-
ments from within the genome of these metastatic cell lines. We
are currently conducting further studies on the capabilities ofthese
13 DNA fragments in promoting metastasis in Rama 37 cells,
either in a collective or an individual manner.
DISCUSSION
The combined techniques of DNA transfection and cell selection
using a drug resistance plasmid together provide a powerful and
important strategy in the study of mechanisms of tumorigenesis
and metastasis. Using this general approach, transformation of
mouse NIH 3T3 fibroblasts previously led to identification of
activated cellular oncogenes such as the ras family. However,
oncogenes that transform NIH 3T3 fibroblasts and produce
fibrosarcomas (Land et al, 1983) do not produce metastases when
transfected into rat benign epithelial cells (Davies et al, 1993).
Earlier work on the generation of metastatic variants of Rama 37
cells by transfection of genomic DNA from rat and human breast
carcinoma cells confirmed the validity of DNA transfection as a
technique with which to assay the metastatic capability ofgenomic
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DNA fragments (Jamieson et al, 1990a; Davies et al, 1994), as
well as that of a variety of cellular oncogenes (Bernstein and
Weinberg, 1988), and the gene for calcium-binding protein p9Ka
(Jamieson et al, 1990b; Davies et al, 1993). Using this technique,
several DNA fragments closely associated with metastasis in
human breast cancer cell lines have been identified (Chen et al,
1997). In this system, the transfected DNA responsible for
inducing metastasis does not code for growth-promoting onco-
genes such as ras etc. as these consistently fail to induce metas-
tasis, in contrast to genes such as that for p9Ka (Jamieson et al,
1990a; Davies et al, 1993). Although the Rama 37 cell system has
been successfully used to assay genomic DNA from breast cell
lines, it has not been used previously to examine the metastatic
ability of DNA from other sources.
In this current work, we describe the first use of this system to
transfect prostatic carcinoma genomic DNA and to generate new
metastatic variants of Rama 37 cells. Dunning rat G cells are only
very weakly metastatic. When this cell line was inoculated into
immunocompetent Copenhagen rats, less than 5% of animals
developed metastases. However, when highly metastatic AT6.1
cells were inoculated into the same host strain, more than 75% of
rats developed metastases (Isaacs et al, 1986). In the present work,
transfection oftotal genomic DNA from weakly metastatic G cells
into benign Rama 37 cells induced metastases in 8.7% of the
experimental animals, whereas the DNA from the highly
metastatic AT6.1 cells induced metastases in 25% of the experi-
mental animals. The mean size of the secondary metastatic
tumours produced by AT6.1-cell DNA transfectants (RMP2) was
larger than the mean size of those induced by G-cell DNA trans-
fectants (RMPI). All rats bearing metastatic tumours produced by
AT6.1-cell DNA transfectants (RMP2) exhibited symptoms of
systemic illness that increased during the later stage of the experi-
ments. However, the animals bearing metastases induced by G-cell
DNA transfectants (RMPI) did not exhibit systemic illness. This
observation indicates that the metastatic capability of the DNA of
AT6.1 cells was greater than that of the G cells, which correctly
reflects the biological characteristics of the Dunning G cell line
and ofthe AT6.1 cell line in our experimental system.
The average sizes of the primary tumours developed in each of
the four groups of animals were very similar (P < 0.03). The
average sizes of primary tumours that produced metastases were
2.15 ± 0.13 cm and 2.07 ± 0.34 cm in rats injected with RMP1 and
RMP2 cells, respectively, when compared with the average sizes
of 2.01 ± 0.39 cm and 2.21 ± 0.41 cm, respectively, of primary
tumours that did not produce metastases but which were devel-
oped from the same stocks oftransfectant cells (RMPl and RMP2
respectively). The differences in average primary tumour sizes
between the metastases-bearing animals and benign tumour-
bearing animals was smaller than those between the animals
within the same category. Therefore, in this system, the sizes of
primary tumours did not relate to the incidence of metastasis. It is
possible that the observation periods, and hence the numbers of
obtained metastases, were arbitrarily limited by the growth of the
primary tumours that remained in situ. However, in previous work
during the development of this system, this observation period
was increased to at least 12 months with no alteration in
metastatic frequencies (Jamieson et al, 1990a). There is also the
possibility of bias in relying on one single animal system for the
detection of genes and/or fragments of DNA that can cause
metastatsis. However, previous studies using the equivalent all
mammary system have identified two genes, p9Ka (S1OOA4)
(Davies et al, 1993) and osteopontin (Oates et al, 1996), that
have been shown subsequently to induce metastasis in other
rodent systems (Ambartsumian et al, 1996; Davies et al, 1996)
or in which reduction of their expression using antisense tech-
nology blocks the development of the metastatic state in other
rodent systems (Behrend et al, 1994; Gardner et al, 1994;
Grigorian et al, 1993).
The incidence of tumours produced in the three groups of
animals inoculated with transfected cells was not significantly
different. However, this incidence was significantly higher than
that produced by the non-transfected, parental, Rama 37 cells.
Although the tumorigenicity of RMP3 cells (Rama 37 cells trans-
fected with Rama 37 DNA) was higher than that of parental (non-
transfected) Rama 37 cells, the transfectants did not produce
metastases in vivo. In contrast, RMP1 (Rama 37 cells transfected
with low metastatic prostatic G-cell DNA) produced lung metas-
tases in two animals; RMP2 (Rama 37 cells transfected with high-
metastatic prostatic AT6.1-cell DNA) produced lung metastases in
five animals. Within this latter group, one animal also developed a
cardiac metastasis. This observation further confirms that produc-
tion of metastases by RMP1 and RMP2 cells is dependent upon
the particular source of the transfected DNA, rather than on the
transfection process itself.
One potential problem encountered in DNA transfection experi-
ments has been to determine the most appropriate size for the
donor DNA fragments. Sequences that are too large reduce trans-
fection efficiency and increase the likely difficulty of their rescue
from recipient cells. Fragments that are too small risk damage to
potential target gene(s). In early transfection studies with 3T3 cells
that led to identification of ras genes, a few restriction enzymes
were used to fragment the donor DNA to avoid cutting within the
target region ofthe DNA (Cooper et al, 1980). In the current study,
HindIII was chosen as the single enzyme to cleave donor DNA.
Partial digestion of genomic DNA with HindIll (at 0.2 unit ig-')
yielded a smear of bands with sizes ranging from 200 to 25 kb,
although the majority ofbands were located in the region between
5 kb and 25 kb (Figure 1). The observation that transfection of
fragmented HindlIl genomic DNA from G cells and AT6.1 cells
results in metastatic transfectants confirms that potential DNA
targets have not been completely damaged by HindIII partial
digestion, as the metastatic capability of DNA in the size range
was not destroyed.
Recovery of donor DNA fragments from within the genome of
cells established from metastatic tumours is the major logistical
difficulty to be overcome in DNA transfection experiments. In
earlier studies, human DNA transfected into 3T3 cells has been
recovered by identification ofhuman specificAlu sequences (Gate
et al, 1995; Hayle et al, 1993). Although several oncogenes have
been identified by this method, the risk involved in this strategy is
that, although Alu sequences are scattered throughout the human
genome they are not contained in every fragment of human DNA
(only 50% according to probability and depending on the sizes of
the fragments). Conversely, the current work has used the specific
strategy of 'flanking' all fragments of donor DNA with short
synthetic DNA oligonucleotide sequences before transfection
(Chen et al, 1997). The short synthetic DNA sequences were engi-
neered in such a manner that not only could they be ligated to the
fragments ofgenomic DNA released by digestion withHindIll but
also were able to ligate both ends of the fragments when cut back
by HindIII. This approach provides a powerful and highly specific
strategy for recovering particular donor DNA fragments from the
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genome ofcells derived from metastases. Screening a DNA library
constructed from the genomic DNA of these new malignant cells
will enable us to identify those 'tagged' fragments, using eitherthe
upper or lower strand ofthe synthetic flanking DNA sequences as
a probe. Furthermore, the sequence comprising 22 of the 45 bases
within the upper strand of the synthetic oligonucleotide flanking
sequence has been specifically engineered for use as a PCR primer
in subsequent amplification procedures (Figure 2). The inherent
symmetry of the designed sequences is such that only this single
primer sequence is required to amplify target genomic DNA frag-
ments flanked by these particular synthetic oligonucleotides.
Therefore, PCR-based sequencing techniques may now be applied
directly to genomic DNA extracted from the newly established
metastatic cells and will provide a direct approach to isolating
those DNA fragments responsible for metastasis in the rat model
system used here. Furthermore, this tested assay system is now
available to be applied to identify metastasis-promoting sequences
contained within genomic DNA from any human malignancy.
Initially, we were concerned that too many fragments of
genomic DNA might be recovered and that these would require
further selection to identify the most important at generating the
metastatic phenotype. However, preliminary experiments using
PCR have identified only 13 distinct fragments in all five
metastatic variants established from both lung and cardiac metas-
tases. There are two likely possibilities for this relatively low
number: first, only those individual cells harbouring the target
fragments can metastasize to secondary sites. Growth of these
cells in vivo has provided a powerful mechanism by which indi-
vidual cells with metastatic capability are selected, and has
filtered-out the majority of cells containing non-specific DNA
fragments. Southern blot data show a significant reduction in the
number of donor DNA fragments in the five new metastatic cell-
lines when compared with the initial three pools of transfectant
cells (Figure 7A). Second, the number of fragments that may be
successfully accumulated by a single cell, while maintaining
general stability ofits genome, is limited. The cells comprising an
individual metastatic tumour may have originated from a single
cell within the primary tumor cell pool. Thus, mechanisms to
ensure genomic stability and survival oftransfected cells, together
with their growth in syngeneic animals, provides a dual process of
selection by which only those cells containing the transfected
genomic DNA that is most important for metastatic dissemination
of the cells to become secondary tumours can survive. The struc-
ture of these 13 fragments recovered by direct PCR is currently
being analysed. A further round of animal assays using these
selected fragments will confirm which, either singly or in combi-
nation, is responsible for generating metastases in this model
system.
Metastatic disease is the major cause of treatment failure and
death from prostatic cancer. A series ofgenetic events is probably
necessary before a prostatic tumour cell develops the capacity
to metastasize (Sandberg, 1997). Such genetic changes include
abnormal expression of metastasis-promoting genes in addition to
a decrease in activities oftumour-suppressor genes. Chromosome-
transfer studies have confirmed human chromosome 17q12-22 to
contain a novel tumour-suppressor gene in this region (Murakami
et al, 1995). Hybridization of the non-metastatic Dunning AT2.1
cell line with highly metastatic prostate carcinoma AT3.1 cells
(Ichikawa et al, 1991) led to the discovery of a small metastasis-
suppressor gene and its human counterpart, KAII located on
human chromosome 1 1.2 (Dong et al, 1995). Conversely, after
differential display analysis of cell lines with distinct behavioural
phenotypes from within the Dunning rat prostatic carcinoma
model, the protein thymosin j15 has been identified to be selec-
tively elevated in the metastatic carcinoma cells (Bao et al, 1996)
and its gene regarded as apossible 'metastasis gene'. A third puta-
tive metastasis-associated gene located on human chromosome 1
has been provisionally identified after linkage analysis (Smith et
al, 1996). However, as yet, there are no experimental data to
locate, or even to support the existence, of a particular gene at
this site. In our own recent work, we found the expression of a
calcium-binding protein p9Ka increases as the increasing
metastatic characteristics of prostate epithelial cells (Ke et al,
1997). In this report, we now provide strong evidence for at least
one metastasis-promoting locus in this rate model system of
prostate cancer. We consider that elevated activity of this DNA,
possibly in conjunction with other DNAs, might play an important
role in promoting metastasis in prostate cancer. Such regions of
DNA that may be ultimately responsible for positively stimulating
cell migration and metastasis will be prime targets for biologically
appropriate molecular therapeutic technique.
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